{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Progression Disease (PD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Number of participants from each treatment cohort with response as defined by Response Assessment in Neuro-oncology (RANO) criteria: Complete Response (CR)= no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; Partial Response (PR)= ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Stable Disease (SD)= \\<50% reduction to \\<25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Progressive Disease (PD)= ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.","groups":[{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG000","title":"Treatment Cohort 1 AA & GBM"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG001","title":"Treatment Cohort 2 Anaplastic PXAs"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG002","title":"Treatment Cohort 3 Other Tumors"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to early termination, results are given per cohort per patient, as the data is meaningless otherwise due to small numbers","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Tumor Radiographic Response Per RANO for 3 Treatment Cohorts","type":"PRIMARY","unitOfMeasure":"Participants"}